Audrey E Kam,Ashiq Masood,Rachna T Shroff
Audrey E Kam
Biliary tract cancers (cholangiocarcinomas and gallbladder cancers) are increasing in incidence and have a poor prognosis. Most patients present with advanced disease, for which the treatment is palliative chemotherapy. Over the past few ye...
Liver transplantation for alcohol-related liver disease in the UK: revised UK Liver Advisory Group recommendations for referral [0.03%]
英国酒精性肝病的肝脏移植：UK Liver Advisory Group 修改后的推荐转诊建议
Steven Masson,Helen Aldersley,Joanna A Leithead et al.
Steven Masson et al.
Liver disease, of which liver cirrhosis is the most advanced stage, constitutes the fourth most common cause of life-years lost in men and women younger than 75 years in England, where mortality rates from liver disease have increased by 25...
Intrahepatic cholestasis of pregnancy: are we expecting too much from ursodeoxycholic acid? - Authors' reply [0.03%]
妊娠期肝内胆汁淤积症：我们对熊去氧胆酸的期望是否太高？——作者回复
Caroline Ovadia,Catherine Williamson
Caroline Ovadia
Intrahepatic cholestasis of pregnancy: are we expecting too much from ursodeoxycholic acid? [0.03%]
妊娠期肝内胆汁淤积症：我们对熊去氧胆酸期望太高了吗？
Sushree Monika Sahoo,Soumya Jagannath Mahapatra
Sushree Monika Sahoo
Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance [0.03%]
来自IBD新领域的应对未满足的需求：南亚IBD联盟
Tina Aswani-Omprakash,Vishal Sharma,Shrinivas Bishu et al.
Tina Aswani-Omprakash et al.
Overcoming imposter syndrome, addressing microaggressions, and defining professional boundaries [0.03%]
克服冒充者综合症、应对微攻击和定义职业边界
Dawn Sears,Sanam Razeghi,Jill Gaidos et al.
Dawn Sears et al.
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial [0.03%]
每周用紫杉醇联合或不联合雷莫芦单抗作为二线疗法治疗晚期胃腺癌或胃食管结合部腺癌（RAINBOW-Asia）的疗效与安全性：一项随机、多中心、双盲、III期试验
Rui-Hua Xu,Yanqiao Zhang,Hongming Pan et al.
Rui-Hua Xu et al.
Background: In the global phase 3 RAINBOW study, ramucirumab plus paclitaxel significantly improved overall survival compared with placebo plus paclitaxel in patients with advanced gastric or gastro-oesophageal junction (...
Grace Lai-Hung Wong,Vincent Wai-Sun Wong
Grace Lai-Hung Wong